PT  - JOURNAL ARTICLE
AU  - J. A. Rauh-Hain
AU  - R. T. Penson
TI  - Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma
AID  - 10.1111/j.1525-1438.2007.01156.x
DP  - 2008 Aug 01
TA  - International Journal of Gynecologic Cancer
PG  - 934--936
VI  - 18
IP  - 5
4099  - http://ijgc.bmj.com/content/18/5/934.short
4100  - http://ijgc.bmj.com/content/18/5/934.full
SO  - Int J Gynecol Cancer2008 Aug 01; 18
AB  - Ovarian clear cell adenocarcinoma (OCCA) is a unique biological subtype of epithelial ovarian cancer, with a similar gene profile to renal cell carcinoma (RCC). Sunitinib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with proven antitumor activity in RCC and a rational biological option for treatment of OCCA. A 60-year-old woman presented with recurrent and refractory stage IA OCCA, after 9 years of remission. Sunitinib was initiated as fifth-line chemotherapy, associated with cystic degeneration of liver metastasis and a short downward trend in her CA125 level. Recurrent and refractory OCCA may respond to Sunitinib. Clinical trials are needed to objectively confirm these findings, as benefit may be limited in patients with extensively pretreated tumors